Hemostemix Inc. (HMTXF)
USD 0.07
(2.96%)
USD 0.07
(2.96%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.32 Million CAD | 4.74% |
| 2022 | 4.12 Million CAD | 178.43% |
| 2021 | 1.48 Million CAD | 746.75% |
| 2020 | 175 Thousand CAD | -91.52% |
| 2019 | 2.06 Million CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | -100.0% |
| 2016 | 1.39 Million CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.61 Million CAD | 3.36% |
| 2024 Q1 | 4.46 Million CAD | 3.36% |
| 2023 FY | 4.32 Million CAD | 4.74% |
| 2023 Q1 | 4.02 Million CAD | -2.51% |
| 2023 Q4 | 4.32 Million CAD | 0.72% |
| 2023 Q3 | 4.29 Million CAD | 2.52% |
| 2023 Q2 | 4.18 Million CAD | 4.05% |
| 2022 Q3 | 2.63 Million CAD | 3.81% |
| 2022 FY | 4.12 Million CAD | 178.43% |
| 2022 Q1 | 1.44 Million CAD | -2.73% |
| 2022 Q2 | 2.54 Million CAD | 76.3% |
| 2022 Q4 | 4.12 Million CAD | 56.41% |
| 2021 Q1 | - CAD | -100.0% |
| 2021 FY | 1.48 Million CAD | 746.75% |
| 2021 Q2 | 1.28 Million CAD | 0.0% |
| 2021 Q4 | 1.48 Million CAD | 11.85% |
| 2021 Q3 | 1.32 Million CAD | 3.46% |
| 2020 Q1 | 268.33 Thousand CAD | -87.0% |
| 2020 Q2 | 15.04 Thousand CAD | -94.39% |
| 2020 Q3 | 15.77 Thousand CAD | 4.82% |
| 2020 Q4 | 175 Thousand CAD | 1009.42% |
| 2020 FY | 175 Thousand CAD | -91.52% |
| 2019 Q3 | 1.96 Million CAD | 302.3% |
| 2019 Q2 | 487.84 Thousand CAD | 0.0% |
| 2019 FY | 2.06 Million CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 Q4 | 2.06 Million CAD | 5.18% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q2 | 1.28 Million CAD | 17.29% |
| 2017 Q3 | - CAD | -100.0% |
| 2017 Q1 | 1.09 Million CAD | -21.07% |
| 2017 FY | - CAD | -100.0% |
| 2016 Q3 | 1.34 Million CAD | 193.14% |
| 2016 FY | 1.39 Million CAD | 0.0% |
| 2016 Q4 | 1.39 Million CAD | 3.17% |
| 2016 Q2 | 460 Thousand CAD | 84.0% |
| 2016 Q1 | 250 Thousand CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.32 Million USD | 78.741% |
| Skye Bioscience, Inc. | 4.61 Million USD | 6.365% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 85.482% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3427.758% |
| Qrons Inc. | 351.84 Thousand USD | -1128.234% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 26.393% |
| BioStem Technologies, Inc. | 4.71 Million USD | 8.276% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -471.473% |
| CSL Limited | 12.18 Billion USD | 99.965% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 90.515% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 90.036% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1294.034% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -585.869% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -16702.768% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 89.512% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -4.841% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -975.405% |
| SQZ Biotechnologies Company | 27.47 Million USD | 84.269% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -85.795% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -355.725% |
| Mesoblast Limited | 118.7 Million USD | 96.359% |
| Marizyme, Inc. | 18.71 Million USD | 76.912% |
| Genus plc | 233.1 Million USD | 98.146% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -47.472% |
| Pharming Group N.V. | 171.54 Million USD | 97.481% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -386.621% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -221.64% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -476.201% |
| ContraFect Corporation | 2.88 Million USD | -50.0% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3089.608% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -198.793% |
| IMV Inc. | 28.88 Million USD | 85.038% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 23.626% |
| MultiCell Technologies, Inc. | 202.58 USD | -2133133.291% |
| ONE Bio Corp. | 19.71 Million USD | 78.08% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 92.483% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -189.112% |
| Q BioMed Inc. | 4.1 Million USD | -5.147% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 86.944% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -251.811% |
| Biomind Labs Inc. | 735.54 Thousand USD | -487.526% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.611% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -42.803% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 66.75% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1101.386% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2953.678% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -91.354% |
| GB Sciences, Inc. | 1.75 Million USD | -145.637% |
| Alpha Cognition Inc. | 1.22 Million USD | -254.114% |
| HST Global, Inc. | 98.31 Thousand USD | -4295.391% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1637.498% |
| Halberd Corporation | 150 Thousand USD | -2781.003% |
| Enzolytics Inc. | 996.33 Thousand USD | -333.739% |
| Agentix Corp. | 50 Thousand USD | -8543.008% |
| Resverlogix Corp. | 6.49 Million USD | 33.423% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1590.782% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 78.392% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 38.9% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -59.541% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -42164.098% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.966% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2054.117% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -80.234% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1784.725% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2807.089% |
| Kadimastem Ltd | 891.22 Thousand USD | -384.894% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1627.344% |
| LadRx Corporation | 33.6 Thousand USD | -12759.323% |
| Cell Source, Inc. | 9.25 Million USD | 53.302% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -471.473% |
| NovAccess Global Inc. | 2.19 Million USD | -96.443% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -1792.268% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1948.349% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 13.275% |
| Mobile Lads Corp. | 484.28 Thousand USD | -792.349% |
| CytoDyn Inc. | 30.07 Million USD | 85.631% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 44.738% |
| SYBLEU INC | 477.5 Thousand USD | -805.027% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 8.738% |
| International Stem Cell Corporation | 4.17 Million USD | -3.435% |
| Bioxytran, Inc. | 1.92 Million USD | -124.494% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6824.045% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -98.152% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 48.034% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 49.662% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -177.825% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1512.501% |
| Neutra Corp. | 54.15 Thousand USD | -7879.733% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -136.148% |
| PureTech Health plc | 25.51 Million USD | 83.061% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -252.999% |
| IXICO plc | 472.02 Thousand USD | -815.528% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 72.121% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 93.059% |
| CSL Limited | 12.18 Billion USD | 99.965% |
| Cellectis S.A. | 92.77 Million USD | 95.342% |